Pharming Group N.V. PHAR
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $376.13M, +26.6% YoY · Filed Apr 2, 2026
Pharming Group N.V. (PHAR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $376.1 million and net income of $2.5 million. Free cash flow was $54.0 million. As of Dec 31, 2025 it held $145.3 million in cash and investments and $17.7 million in total debt.
Revenue
$376.13M
+26.6% vs prior year
Net income
$2.54M
+121.4% vs prior year
Operating cash flow
$54.71M
+3147.8% vs prior year
Free cash flow
$53.96M
+2187.4% vs prior year
EPS
$0.00
+122.2% vs prior year
Dividend per share
None
Shares outstanding
701.68M
+3.1% vs prior year
Net cash
$127.59M
FY 2025
Operating margin
6.9%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PHAR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Netherlands
- Headquarters
- Leiden, Netherlands
- SEC filer status
- Accelerated filer
- SEC CIK
- 1828316
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $376.1M | $297.2M | $245.3M | $205.6M | $198.9M |
| Operating income | $25.8M | -$8.6M | -$5.4M | $18.2M | $13.6M |
| Net income | $2.5M | -$11.8M | -$10.5M | $13.7M | $16.0M |
| Diluted EPS | $0.00 | -$0.02 | -$0.02 | $0.02 | $0.02 |
| Operating cash flow | $54.7M | -$1.8M | -$17.3M | $22.5M | $37.8M |
| Free cash flow | $54.0M | -$2.6M | -$18.7M | $21.1M | $27.1M |
| Total assets | $500.0M | $400.0M | $462.9M | $425.8M | $397.3M |
| Stockholders' equity | $277.1M | $221.1M | $218.8M | $204.6M | $192.9M |
| Cash and investments | $145.3M | $54.9M | $61.7M | $207.3M | $191.9M |
| Total debt | $17.7M | $29.9M | $33.1M | $33.3M | $20.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 6, 2026 | Nov 6, 2026 |
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Oct 22, 2026 | Oct 22, 2026 |
| 6-K | Current report (foreign issuer) | Oct 14, 2026 | Oct 14, 2026 |
| 6-K | Current report (foreign issuer) | Sep 29, 2026 | Sep 29, 2026 |
| 6-K | Current report (foreign issuer) | Sep 25, 2026 | Sep 25, 2026 |
All 149 Pharming Group N.V. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.